CamAPS Liberty: A New Era in Automated Insulin Delivery for Type 1 Diabetes

CamDiab has unveiled CamAPS Liberty, a groundbreaking fully closed-loop automated insulin delivery feature integrated into its CamAPS FX app. Announced at the Advanced Technologies & Treatments for Diabetes (ATTD) Congress 2026 in Barcelona, Liberty represents a significant advancement in diabetes management, aiming to reduce the burden of carbohydrate counting and pre-meal bolus calculations for individuals with type 1 diabetes.

What is CamAPS Liberty?

CamAPS Liberty is designed to automate insulin delivery, offering support during challenging daily routines. When activated, the system proactively anticipates and manages glucose fluctuations within defined safety limits, effectively pausing the need for manual carbohydrate counting and bolus delivery. This innovation is intended to improve the mental energy, well-being, and quality of life for CamAPS FX users while maintaining effective glucose control [Drug Delivery Business].

How Does it Work?

Liberty utilizes an enhanced version of the CamAPS algorithm to anticipate and respond to glucose changes. Users can enable a fully closed-loop mode, eliminating the need for carbohydrate counting or pre-meal insulin boluses. Despite the automation, users retain access to existing controls within the CamAPS FX app, including Boost, Ease-off, Add Meal, and manual boluses, allowing for personalized adjustments [Diabetech]. Automated data sharing with care teams continues through Companion, Glooko, mylife Cloud, and the CamAPS two-week PDF report.

Compatibility and Approvals

The mylife CamAPS FX app, developed by CamDiab and approved by the FDA, works in conjunction with MyLife’s insulin delivery pumps. The iOS version of the app is compatible with leading continuous glucose monitors (CGMs), including the FreeStyle Libre 3 and Libre 3 Plus from Abbott and the Dexcom G6 [Drug Delivery Business]. CamDiab received notified body approval for the fully closed-loop algorithm in January 2026 and is rolling it out to mylife Loop AID and Dana pump users, pending market-specific approvals.

A Milestone in Diabetes Technology

“CamAPS Liberty represents a huge milestone for the diabetes community, marking the dawn of commercially available fully closed-loop technology,” stated Roman Hovorka, founder of CamDiab. “Our focus has always been on people, not just innovation. By embedding it into our CamAPS FX app, CamDiab is ensuring this progress remains accessible, equitable and truly centered around the needs of those living with type 1 diabetes.” [Drug Delivery Business]

Competitive Landscape

CamAPS Liberty currently stands as the first commercially available fully closed-loop option for individuals with type 1 diabetes. This launch positions CamDiab ahead of competitors like Insulet, whose fully closed-loop system for type 2 diabetes remains in earlier stages of development [Diabetech].

Important Considerations

The CamAPS Liberty feature has not been tested for use during pregnancy or in children under the age of 13 and is therefore not currently recommended for these populations [Diabetech]. CamDiab emphasizes that the feature complements, but does not replace, an existing diabetes management plan. It is designed to provide additional support during periods of stress, travel, or busy schedules, reducing the cognitive and emotional load associated with diabetes management.